A Stronger Cannabis Signal Could Mean Lower Raw Fluorescence in a Competitive Urine Assay

In the portable microfluidic urine assay, increasing drug concentrations reduced the raw test signal. The competitive design explains why a lower fluorescence response can correspond to a more positive cannabinoid result.

The sample competed with labeled material

Ko and colleagues used fluorescent antigen-conjugated beads and immobilized drug-specific antibodies. With a drug-free specimen, labeled material could bind and produce a strong test response. Drug in the specimen competed for antibody binding, reducing the measured test fluorescence.

The reported index changed the signal’s direction

The reader compared test and reference responses and then normalized the specimen ratio to the cutoff ratio. Because the specimen ratio appeared in the denominator, a lower raw ratio could yield a higher cutoff index. Reading the instrument’s raw fluorescence as though it increased directly with urinary THC-COOH would invert the intended interpretation.

Signal interpretation requires the actual workflow

The design is useful for understanding laboratory output and troubleshooting, but does not make every low signal a valid positive. Reference performance, preparation and the decision rule still matter. This specific assay measured urinary THC-COOH rather than parent THC in blood. Its antibody signal and calculated index are analytical outputs; neither directly measures a consumed dose, timing of use or functional impairment. When reviewing an instrument report, identify whether the number is raw fluorescence, a test/reference ratio or the normalized classification index before comparing it with another method.

Related analysis: what the urine platform measured.

Research cited

Ko and colleagues. On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine. ACS Omega (2026). DOI: 10.1021/acsomega.5c11027.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

CBD Memory Findings in Cerebral-Malaria Mice Involved Adjunctive Antimalarial Treatment

A mouse cerebral-malaria experiment summarized in the CBD brain review reported memory findings when CBD was added to artesunate. The observation concerned adjunctive treatment in an infectious-disease model, rather than CBD alone as a general memory enhancer. The disease and co-treatment belonged in the result The review describes CBD treatment…

Spread the love

Read Article: CBD Memory Findings in Cerebral-Malaria Mice Involved Adjunctive Antimalarial Treatment

Serotonin Blockade Qualified CBD Pain Mechanisms Differently Across Rat Models

Rat experiments summarized in the CBD brain review found different degrees of interference with CBD-related pain responses after serotonin-receptor blockade. The evidence did not establish one exclusive mechanism for every model. The diabetic and nerve-injury models differed In male diabetic rats, the review reports attenuation of mechanical allodynia with CBD…

Spread the love

Read Article: Serotonin Blockade Qualified CBD Pain Mechanisms Differently Across Rat Models

Attrition and Incomplete Dosing Complicated an Observational CBD Pain Report

An observational CBD study summarized in the brain-function review reported improvement in pain patients but had substantial participant loss and incomplete dosing information. Those limitations constrained attribution of the change to CBD. The clinical groups did not report one uniform response The review describes Gulbransen and colleagues’ exploratory quality-of-life study….

Spread the love

Read Article: Attrition and Incomplete Dosing Complicated an Observational CBD Pain Report

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us